Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study
Publication year
2019Source
Journal of the American Academy of Dermatology, 80, 1, (2019), pp. 70-+ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Dermatology
Journal title
Journal of the American Academy of Dermatology
Volume
vol. 80
Issue
iss. 1
Page start
p. 70
Page end
p. +
Subject
All institutes and research themes of the Radboud University Medical Center; Radboudumc 5: Inflammatory diseases RIHS: Radboud Institute for Health SciencesThis item appears in the following Collection(s)
- Academic publications [188575]
- Faculty of Medical Sciences [74223]
Upload full text
Use your RU credentials (u/z-number and password) tolog in with SURFconextto upload a file for processing by the repository team.